Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post‐autologous stem cell transplantation lenalidomide maintenance therapy
Open Access
- 13 February 2021
- journal article
- letter
- Published by Wiley in American Journal of Hematology
- Vol. 96 (5), E157-E162
- https://doi.org/10.1002/ajh.26125
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplantNature Communications, 2020
- Clonal hematopoiesis in human aging and diseaseScience, 2019
- Clinical Applications and Utility of a Precision Medicine Approach for Patients With Unexplained CytopeniasMayo Clinic Proceedings, 2019
- Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular DiseaseThe New England Journal of Medicine, 2017
- Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for LymphomaJournal of Clinical Oncology, 2017
- Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control studyThe Lancet Oncology, 2017
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaThe Lancet Oncology, 2016
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemiaBlood, 2016
- Age-Related Clonal Hematopoiesis Associated with Adverse OutcomesThe New England Journal of Medicine, 2014
- Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient dataThe Lancet Oncology, 2014